Stay updated on Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab

Sign up to get notified when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.
Latest website image capture
Clouds background image

Latest updates to the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page

  1. Check
    5 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the afatinib–pembrolizumab lung cancer study is displayed with study details, eligibility criteria, outcome measures, locations, publications, and study documents.
    Difference
    56%
    Check dated 2026-11-11T01:44:06.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-03T23:58:36.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    A site-wide NIH notice about terminology during the agency transition appears above the ClinicalTrials.gov page, and the displayed site revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-21T00:07:21.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T00:11:51.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record and blocking access to the trial details.
    Difference
    18%
    Check dated 2026-09-23T00:06:37.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.7.0 instead of v3.6.6, indicating an update to the site's interface version. This change relates to UI/versioning and does not alter the study details or content.
    Difference
    0.1%
    Check dated 2026-09-15T23:25:42.000Z thumbnail image

Stay in the know with updates to Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab

Enter your email address, and we'll notify you when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.